The FDA's drug voucher initiative is facing fresh scrutiny, with a Democratic representative expressing serious concerns about its implementation and the adherence of senior officials to federal ethics regulations.
In a letter dated Tuesday, Representative Jake Auchincloss from Massachusetts criticized how the program has been managed and questioned its legal foundation, pointing out that Congress has not authorized this plan.
This renewed examination comes just as the FDA is planning to host an employee town hall meeting that afternoon regarding the Commissioner’s National Priority Voucher program, as reported by three agency staff who requested anonymity to discuss sensitive internal matters.
Through this voucher program, pharmaceutical companies are offered expedited review times of one to two months for new drugs that align with what the agency deems as "national interests." This initiative is central to FDA Commissioner Marty Makary's ambition to reduce regulatory hurdles and challenge existing norms within the agency.
However, the program has sparked significant controversy, both within the organization and externally. Several high-ranking officials have reportedly hesitated to approve drugs under this new system, as previously detailed in AP reports.
"It is vital for the public to have clarity surrounding the 'voucher' program, which has allowed drug approvals to be driven predominantly by the political leadership at the FDA in an unprecedented way," stated Auchincloss, who serves on a House health subcommittee.
He emphasized that the FDA has not made available or disclosed financial disclosure forms for eight senior officials who participate in deciding which drugs should gain priority under the voucher system. This group notably includes individuals closely associated with Health Secretary Robert F. Kennedy Jr., such as Deputy FDA Commissioner Dr. Sara Brenner, Dr. Vinay Prasad, who oversees vaccine regulation, and Dr. Tracy Beth Hoeg, director of the FDA’s drug center.
These financial disclosure forms, collected annually by the Office of Government Ethics, are essential as they detail investments, outside income, and other financial interests of senior government officials and their spouses. Such transparency is crucial to prevent potential conflicts of interest at the FDA, especially considering that staff often deal with multi-billion-dollar publicly traded companies.
A spokesperson from the Department of Health and Human Services has not yet responded to inquiries from the AP regarding Auchincloss’s letter.
In his correspondence, Auchincloss also raises doubts about whether the FDA possesses the legal authority to implement the voucher program independently, without Congressional approval, which is typically necessary for establishing such programs. He pointed out that the FDA’s legal department was neither consulted nor provided any findings to justify the agency’s assertion that it could independently initiate the program.
Furthermore, Auchincloss notes that FDA officials did not reply to two prior letters he sent last year seeking information. In his latest letter, he demands that the agency either confirm or deny his findings.
In November, Senator Bernie Sanders of Vermont and Representative Frank Pallone of New Jersey also sent a letter requesting answers to fifteen questions regarding the FDA’s voucher initiative. Pallone is the leading Democrat on the House Energy and Commerce Committee, which supervises health agencies.
According to committee staff, the agency has not responded to that letter either.
